Herve Watier

Summary

Affiliation: Universite Francois-Rabelais, Faculte de Medecine
Location: Tours, France

Publications

  1. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
  2. ncbi Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
    Severine Loisel
    Universite de Bretagne Occidentale, Laboratoire de Thérapie Cellulaire et d Immunobiologie du Cancer, EA 2216, 29609 Brest Cedex, France
    Crit Rev Oncol Hematol 62:34-42. 2007
  3. ncbi CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia
    Florence Dommange
    CHRU de Tours, Laboratoire d Hematologie, Service d Hématologie et Thérapie Cellulaire
    FASEB J 20:1913-5. 2006
  4. doi Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype
    Nicolas Congy-Jolivet
    EA3853 Immuno Pharmaco Genetique des Anticorps thérapeutiques, Universite Francois Rabelais de Tours, Tours, France
    Cancer Res 68:976-80. 2008
  5. doi Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
    G Cartron
    EA3853, Immuno Pharmaco Génétique des Anticorps Thérapeutiques, Universite Francois Rabelais, Tours
    Ann Oncol 19:1485-7. 2008
  6. doi Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
  7. ncbi Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship
    Sébastien Dall'Ozzo
    Laboratoire d Immunologie, Centre Hospitalier Regional et Universitaire, Tours, France
    Cancer Res 64:4664-9. 2004
  8. ncbi From the bench to the bedside: ways to improve rituximab efficacy
    Guillaume Cartron
    UPRES EA Immuno Pharmaco Génétique des Anticorps thérapeutiques, UPRES EA, Universite Francois Rabelais, Tours, France
    Blood 104:2635-42. 2004
  9. ncbi Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies
    Julien Lejeune
    J Clin Oncol 26:5489-91; author reply 5491-2. 2008
  10. doi Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    David Daydé
    Genetique, Immunothérapie, Chimie et Cancer, Universite Francois Rabelais, Tours, France
    Blood 113:3765-72. 2009

Collaborators

Detail Information

Publications28

  1. ncbi Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene
    Guillaume Cartron
    Service d Oncologie Médicale et Maladies du Sang et Laboratoire d Immunologie, Centre Hospitalier Régional et Universitaire de Tours, 37044 Tours Cedex, France
    Blood 99:754-8. 2002
    ..This finding will certainly give rise to new pharmacogenetic approaches to the management of patients with non-Hodgkin lymphomas...
  2. ncbi Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
    Severine Loisel
    Universite de Bretagne Occidentale, Laboratoire de Thérapie Cellulaire et d Immunobiologie du Cancer, EA 2216, 29609 Brest Cedex, France
    Crit Rev Oncol Hematol 62:34-42. 2007
    ..In doing so, this article aims to provide a critical review of the animal models used in preclinical studies of mAbs for cancer treatment. In particular, their relevance, advantages and limitations will be discussed...
  3. ncbi CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia
    Florence Dommange
    CHRU de Tours, Laboratoire d Hematologie, Service d Hématologie et Thérapie Cellulaire
    FASEB J 20:1913-5. 2006
    ....
  4. doi Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype
    Nicolas Congy-Jolivet
    EA3853 Immuno Pharmaco Genetique des Anticorps thérapeutiques, Universite Francois Rabelais de Tours, Tours, France
    Cancer Res 68:976-80. 2008
    ..We conclude that increased binding and functional and clinical responses associated with the high-affinity Fc gamma RIIIa-158V are unrelated to an increased expression of this allotype...
  5. doi Neutrophil role in in vivo anti-lymphoma activity of rituximab: FCGR3B-NA1/NA2 polymorphism does not influence response and survival after rituximab treatment
    G Cartron
    EA3853, Immuno Pharmaco Génétique des Anticorps Thérapeutiques, Universite Francois Rabelais, Tours
    Ann Oncol 19:1485-7. 2008
    ..We formulated the hypothesis that if neutrophils are critical cells for in vivo rituximab activity, FcgammaRIIIb-NA1/NA2 polymorphism could influence the response to rituximab...
  6. doi Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
    ..We aimed to study the influence of immunosuppressives discontinuation in patients in remission with combination therapy in an open-label, randomized, controlled trial...
  7. ncbi Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship
    Sébastien Dall'Ozzo
    Laboratoire d Immunologie, Centre Hospitalier Regional et Universitaire, Tours, France
    Cancer Res 64:4664-9. 2004
    ..Rituximab administration could therefore be adjusted according to FCGR3A genotype...
  8. ncbi From the bench to the bedside: ways to improve rituximab efficacy
    Guillaume Cartron
    UPRES EA Immuno Pharmaco Génétique des Anticorps thérapeutiques, UPRES EA, Universite Francois Rabelais, Tours, France
    Blood 104:2635-42. 2004
    ..A better understanding of how rituximab acts in vivo should make it possible to develop new and more effective therapeutic strategies...
  9. ncbi Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies
    Julien Lejeune
    J Clin Oncol 26:5489-91; author reply 5491-2. 2008
  10. doi Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
    David Daydé
    Genetique, Immunothérapie, Chimie et Cancer, Universite Francois Rabelais, Tours, France
    Blood 113:3765-72. 2009
    ..Furthermore, rituximab exposure influenced response and survival. Finally, using a pharmacokinetic-pharmacodynamic model, we demonstrated that tumor burden significantly influenced rituximab efficacy...
  11. pmc Therapeutic antibodies in ophthalmology: old is new again
    Charlotte Magdelaine-Beuzelin
    Universite Francois Rabelais de Tours, France
    MAbs 2:176-80. 2010
    ....
  12. doi The airways, a novel route for delivering monoclonal antibodies to treat lung tumors
    Agnès Maillet
    INSERM U618, Universite Francois Rabelais de Tours, Tours, France
    Pharm Res 28:2147-56. 2011
    ..We have shown that cetuximab, a chimeric anticancer anti-EGFR mAb, is suitable for airway delivery as it resists the physical constraints of aerosolization, and have evaluated the aerosol delivery of cetuximab in vivo...
  13. pmc Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases
    Emilie Ducourau
    Universite Francois Rabelais de Tours, Centre National de la Recherche Scientifique UMR 6239 GICC, 3 rue des Tanneurs, F 37041 Tours Cedex 1, France
    Arthritis Res Ther 13:R105. 2011
    ..We studied the association of infliximab concentration at treatment initiation and development of ATI as well as the association of the presence of ATI and maintenance of infliximab...
  14. ncbi Pharmacokinetics of rituximab and its clinical use: thought for the best use?
    Guillaume Cartron
    Universite Francois Rabelais, UPRES EA 3853 Immuno Pharmaco Génétique des Anticorps thérapeutiques IPGA, Tours, France
    Crit Rev Oncol Hematol 62:43-52. 2007
    ..This review focuses on the current knowledge on rituximab pharmacokinetics and on factors influencing individual exposure and suggests ways to improve its clinical use...
  15. ncbi An enzyme-linked immunosorbent assay for therapeutic drug monitoring of infliximab
    David Ternant
    Universite Francois Rabelais, Immuno Pharmaco Genetics of Therapeutic Antibodies, Tours, France
    Ther Drug Monit 28:169-74. 2006
    ..Data were described using a 1-compartment population pharmacokinetic model. Terminal elimination half-life was 10.9 days. This method is rapid, accurate, and reproducible, and may be useful in therapeutic drug monitoring of infliximab...
  16. ncbi [Biomarkers and pharmacokinetic-pharmacodynamic studies of immunosuppressive agents]
    Gilles Paintaud
    Service de Pharmacologie, Hopital Bretonneau, CHU de Tours, Tours, France
    Therapie 59:179-83. 2004
    ..Pharmacodynamic indirect response models are particularly relevant in this instance...
  17. ncbi The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes
    Yves Gruel
    Department of Hematology Hemostasis, Centre Hospitalier Universitaire Tours, Institut National de la Santé et de la Recherche Médicale U618, Tours, France
    Blood 104:2791-3. 2004
    ..01). Since anti-H/PF4 Abs are mainly IgG1 and IgG3, clearance of sensitized platelets may be increased in patients homozygous for the FcgammaRIIIa-158V allotype, thus contributing to the development of thrombocytopenia...
  18. doi [Monoclonals antibodies: a recent and major therapeutic advance]
    Gilles Paintaud
    Universite Francois Rabelais de Tours, GICC, Tours, France
    Therapie 64:1-7. 2009
    ..At present, about twenty monoclonal antibodies are on the market, and a large number is under development...
  19. doi IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab
    Charlotte Magdelaine-Beuzelin
    Universite Francois Rabelais de Tours, France
    Pharmacogenet Genomics 19:383-7. 2009
    ..This allelic form may be immunogenic in patients that are homozygous for the G1m3 allotype commonly expressed in Caucasoid populations...
  20. ncbi Can sciatica induced by disc herniation be treated with tumor necrosis factor alpha blockade?
    Philippe Goupille
    François Rabelais de Tours University, EA 3853 Immuno Pharmaco Génétique des Anticorps thérapeutiques, Tours Cedex 9, France
    Arthritis Rheum 56:3887-95. 2007
  21. ncbi Structure-function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
    Charlotte Magdelaine-Beuzelin
    Universite Francois Rabelais de Tours, EA 3853 Immuno Pharmaco Génétique des Anticorps thérapeutiques, France
    Crit Rev Oncol Hematol 64:210-25. 2007
    ..Overall, the IMGT standards appear as a first and crucial step in the evaluation of recombinant antibodies...
  22. ncbi Human choriocarcinoma cell resistance to natural killer lysis due to defective triggering of natural killer cells
    Tony Avril
    EA 3249 Cellules Hématopoïétiques, Hémostase et Greffe, Faculte de Medecine, Tours, France
    Biol Reprod 69:627-33. 2003
    ..These results indicate that the resistance of CC to lysis results primarily from defective NK cell activation, at least partially due to the lack of expression of ligands, such as CD48, involved in the triggering of NK cells...
  23. ncbi Association of donor TNFRSF6 (FAS) gene polymorphism with acute rejection in renal transplant patients: a case-control study
    Sandrine Cappellesso
    UPRES EA 3249 Cellules Hématopoïétiques, Hémostase et Greffe, Universite de Tours, Faculte de Medecine, and Laboratoire d Immunologie and Service de Néphrologie et Immunologie Clinique, CHRU de Tours, Tours Cedex, France
    Nephrol Dial Transplant 19:439-43. 2004
    ....
  24. ncbi Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality
    Nicolas Congy-Jolivet
    Universite Francois Rabelais de Tours, EA 3853 Immuno Pharmaco Génétique des Anticorps thérapeutiques, 10 boulevard Tonnelle, 37032 Tours Cedex, France
    Crit Rev Oncol Hematol 64:226-33. 2007
    ..The aim of this review is to describe the main mechanisms of action of recombinant mAbs in relation to this structural and functional duality...
  25. doi [Neonatal Fc receptor, key control of immunoglobulins biodistribution]
    Charlotte Magdelaine-Beuzelin
    C Magdelaine Beuzelin, H Watier, M Ohresser, Universite Francois Rabelais de Tours, France
    Med Sci (Paris) 25:1053-6. 2009
    ..FcRn is thus a key partner in the pharmacokinetics of therapeutic antibodies, opening interesting prospects for optimisation of their use...
  26. ncbi Rapid single-step FCGR3A genotyping based on SYBR Green I fluorescence in real-time multiplex allele-specific PCR
    Sébastien Dall'Ozzo
    EA 3249, Group, Laboratoire d Immunologie, Faculte de Medecine, 2 bis Boulevard Tonnelle, 37032 Cedex, Tours, France
    J Immunol Methods 277:185-92. 2003
    ..Although this method requires expensive equipment, it is inexpensive in terms of consumables. It is also very rapid, reliable and suitable for large-scale analysis...
  27. doi [From the ancient serotherapy to naked antibodies: a century of successful targeted therapies]
    Herve Watier
    Universite Francois Rabelais de Tours, Laboratoire d Immunologie, Faculte de Medecine, 10, boulevard Tonnelle, 37032 Tours Cedex, France
    Med Sci (Paris) 25:999-1009. 2009
    ..This overview will finally offer the opportunity to introduce a new pharmacological classification of the entire class of unconjugated -therapeutic antibodies...
  28. ncbi Variability factors in the clinical response to recombinant antibodies and IgG Fc-containing fusion proteins
    Herve Watier
    Universite Francois Rabelais de Tours, EA 3853 IPGA Immuno Pharmaco Genetics of therapeutic Antibodies, Faculte de Medecine, 37032 Tours Cedex, France
    Expert Opin Biol Ther 5:S29-36. 2005
    ..Known variability factors are reviewed and classified according to their relationship with the paratope (antigen binding site) of the antibodies, with other parts of the IgGs (mostly Fc) or with IgG epitopes (antigenic motifs)...